Sever Pharma Solutions has previously supported Silo in earlier development stages of the ketamine implants and successfully validated the delivery system through extensive long-term in-vitro release testing and drug product characterization.

The expanded collaboration will enable further pre-clinical development of SP-26, focusing on refining time-released, dose-controlled formulations essential for the implant’s therapeutic efficacy and safety profile, the companies state.

“We are pleased to continue our collaboration with Sever Pharma Solutions as we move forward with further pre-clinical testing of our novel non-opioid chronic pain therapeutic,” says Silo Pharma’s CEO Eric Weisblum. 

“This project together with Silo Pharma exemplifies our commitment to leveraging our specialized capabilities in polymer-based drug delivery systems to help bring novel, non-opioid treatment options closer to patients in need,” says Tony Listro, VP, Technology and Site Lead of Sever Pharma Solutions’ Putnam, CT USA facility.